Table 2.
PAI-1, inflammatory markers and serobiochemical variables of patients with coronary artery disease (n = 75) in secondary prevention of cardiovascular disease at the inclusion
| Groups | |||
|---|---|---|---|
| A | B | C | |
| (n = 25) | (n = 25) | (n = 25) | |
| Plasminogen activator inhibitor type, ng/mL | 18.7 ± 14.4 | 19.8 ± 14.9 | 17.2 ± 10.3 |
| High-sensitivity C-reactive protein, mg/L | 3.3 ± 2.2 | 3.5 ± 2.3 | 3.9 ± 4.1 |
| Adiponectin, μg/mL | 11.0 ± 5.8 | 11.2 ± 4.5 | 12.4 ± 5.6 |
| Tumor necrosis factor-α, pg/mL | 13.7 ± 8.6 | 14.2 ± 8.7 | 14.9 ± 8.6 |
| Interleukin-6, pg/mL | 2.6 ± 1.7 | 2.2 ± 1.7 | 2.3 ± 1.8 |
| Interleukin-10, pg/mL | 19.6 ± 12.4 | 22.7 ± 16.1 | 23.05 ± 16.7 |
| Interleukin-6/Interleukin-10 | 0.16 ± 0.14 | 0.12 ± 0.12 | 0.12 ± 0.1 |
| Soluble CD40 ligand, ng/mL | 7.5 ± 3.9 | 6.5 ± 4.4 | 6.1 ± 3.6 |
| Soluble vascular adhesion molecule type 1, ng/mL | 1063 ± 253 | 1033 ± 368 | 1030 ± 463 |
| Total cholesterol, mg/dL | 162.4 ± 36.5 | 156.7 ± 30.9 | 165.6 ± 35.2 |
| Low-density lipoprotein cholesterol, mg/dL | 89.1 ± 30.7 | 81.4 ± 26.4 | 92.4 ± 31.5 |
| High-density lipoprotein cholesterol, mg/dL | 39.5 ± 8.7 | 43.2 ± 10.2 | 44.8 ± 7.2 |
| LDLc/HDLc, mg/dL | 2.3 ± 0.2 | 1.9 ± 0.2 | 2.0 ± 0.1 |
| non-HDLc, mg/dL | 140 ± 10 | 127 ± 7 | 135 ± 11 |
| Triglycerides, mg/dL | 139 ± 61 | 138 ± 49 | 123 ± 48 |
| Fibrinogen, g/L | 3.3 ± 0.5 | 3.6 ± 0.5 | 3.5 ± 0.5 |
| D-Dimer, mg/L | 0.13 ± 0.07 | 0.12 ± 0.06 | 0.13 ± 0.05 |
| Aspartate transaminase, U/L | 24 ± 10 | 24 ± 6 | 30 ± 11 |
| Alanine transaminase, U/L | 27 ± 15 | 33 ± 17 | 33 ± 17 |
| Alkaline phosphatase, U/L | 184 ± 60 | 190 ± 57 | 180 ± 45 |
| Creatine phosphokinase, U/L | 112 ± 69 | 114 ± 52 | 154 ± 67 |
| γ-Glutamyl transferase, U/L | 39 ± 21 | 40 ± 27 | 34 ± 17 |
| Lactate dehydrogenase, U/L | 305 ± 46 | 317 ± 59 | 361 ± 72 |
| Glucose, mg/dL | 121 ± 51 | 122 ± 20 | 127 ± 45 |
| Glycated hemoglobin, % | 6.3 ± 1.3 | 6.4 ± 0.4 | 6.6 ± 1.3 |
| Tyroid stimulating hormone, mU/L | 2.4 ± 1.2 | 1.7 ± 0.8 | 1.7 ± 1.2 |
| Thyroxine, ng/dL | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.2 ± 0.2 |
| Bilirubin, mg/dL | 0.6 ± 0.3 | 0.5 ± 0.2 | 0.6 ± 0.2 |
| Creatinin, mg/dL | 1.0 ± 0.3 | 1.0 ± 0.3 | 0.9 ± 0.2 |
| Urate, mg/dL | 6.5 ± 1.6 | 6.2 ± 1.5 | 5.8 ± 1.5 |
| Albumin, g/L | 45.2 ± 2.4 | 44.4 ± 2.6 | 44.6 ± 2.1 |
Values are expressed as mean ± SD. A placebo group, B grape extract group (GE); C resveratrol-containing grape extract group (GE-RES). No inter-group differences (p < 0.05) were found at baseline